標(biāo)題：Research Grade Trastuzumab曲妥珠單抗,AntibodySystem Laboratories

鏈接：https://www.antibodysystem.com/product/10037.html

名稱：Research Grade Trastuzumab曲妥珠單抗

別名：Trastuzumab曲妥珠單抗，timigutuzumab, 4D5-8, 4D5V8, Herceptin, rhuMab HER2,

CAS: 180288-69-1

貨號：DHC09601

適用物種：Human

寄主物種：Humanized

形式：Liquid

純度：>95%

克隆性：Monoclonal

同種型：IgG1, kappa

應(yīng)用：Research Grade Biosimilar

UniProt：P04626

靶點：p185erbB2, HER2, NGL, Tyrosine kinase-type cell surface receptor HER2, NEU, MLN 19, Proto-oncogene Neu, MLN19, ERBB2, Proto-oncogene c-ErbB-2, CD340, Receptor tyrosine-protein kinase erbB-2, Metastatic lymph node gene 19 protein

用途范圍：僅用于科研

儲存：Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.

產(chǎn)品購買聯(lián)系方式：027-65279366 /18162686757

郵箱：biolab-reagents@atagenix.com

QQ：2663991332

 

參考文獻(xiàn)：

Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. PMID: 36495879

Trastuzumab Deruxtecan: First Approval. PMID: 32144719

The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer. PMID: 36587473

11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. PMID: 28215665

Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors. PMID: 32213540

[Trastuzumab and its biosimilars]. PMID: 29813044

Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial. PMID: 33480963

Trastuzumab Deruxtecan: Changing the Destiny of HER2 Expressing Solid Tumors. PMID: 33946310

Disrupting Circadian Rhythm via the PER1-HK2 Axis Reverses Trastuzumab Resistance in Gastric Cancer. PMID: 35255118

Glutamine metabolic microenvironment drives M2 macrophage polarization to mediate trastuzumab resistance in HER2-positive gastric cancer. PMID: 37434399

Targeting HER2-positive breast cancer: advances and future directions. PMID: 36344672

Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers. PMID: 37279095

Trastuzumab Deruxtecan in HER2-Low Breast Cancer. Reply. PMID: 36130006

Adjuvant trastuzumab: a 10-year overview of its benefit. PMID: 27883296

Management of patients with HER2-positive metastatic breast cancer after trastuzumab deruxtecan failure. PMID: 37467660

Trastuzumab Deruxtecan for Breast Cancer. PMID: 35704495

Flashback Foreword: Activity of First-Line Trastuzumab. PMID: 36921334

Monitoring Trastuzumab Resistance and Cardiotoxicity: A Tale of Personalized Medicine. PMID: 26231486

Trastuzumab deruxtecan for breast cancer: do patients experience a comprehensive benefit? PMID: 37349024

Trastuzumab Deruxtecan in HER2-Low Breast Cancer. PMID: 36130005

Trastuzumab Deruxtecan for Breast Cancer. Reply. PMID: 35704496

Efficacy and safety of the trastuzumab biosimilar candidate CT-P6. PMID: 29482364

Trastuzumab administration during pregnancy: an update. PMID: 33902516

Trastuzumab-induced human cardiomyocyte damage through the Notch2/JAK2/STAT3 pathway. PMID: 37567042

Safety of trastuzumab deruxtecan: A meta-analysis and pharmacovigilance study. PMID: 36200429

Association between trastuzumab and papilledema. PMID: 33419593

How I treat HER2-positive early breast cancer: how long adjuvant trastuzumab is needed? PMID: 35272131

Trastuzumab-based therapy is effective for salivary duct carcinoma: Case report and review of the literature. PMID: 30827840

The novel beta-TrCP protein isoform hidden in circular RNA confers trastuzumab resistance in HER2-positive breast cancer. PMID: 37783059

Totality of Scientific Evidence in the Development of ABP 980, a Biosimilar to Trastuzumab. PMID: 31620980

Trastuzumab Deruxtecan DESTINY for Some Cancers. PMID: 32487568

Trastuzumab-Induced Thrombocytopenia Correlated by Drug-Dependent Platelet Antibodies. PMID: 33270522

Blocking soluble TNFalpha sensitizes HER2-positive breast cancer to trastuzumab through MUC4 downregulation and subverts immunosuppression. PMID: 36889811

Trastuzumab immunogenicity development in patients' sera and in laboratory animals. PMID: 33607941

Could Some Reports of Trastuzumab Cardiotoxicity Be a Surveillance Artifact? PMID: 35878103

Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer. PMID: 36773612

Trastuzumab and pertuzumab in hemodialysis: A case report. PMID: 33779370

Trastuzumab-based near-infrared photoimmunotherapy in xenograft mouse of breast cancer. PMID: 36259134

Trastuzumab emtansine and cost-based decision making. PMID: 28091366

Is weight-based IV dosing of trastuzumab preferable to SC fixed-dose in some patients? A systematic scoping review. PMID: 33799233

Structure-Activity Relationships of Antibody-Drug Conjugates: A Systematic Review of Chemistry on the Trastuzumab Scaffold. PMID: 35801843